Dasatinib is a tyrosine kinase inhibitor [1]. It is used to treat certain types of leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1][2]. The drug works by blocking specific enzymes that cancer cells need to grow and multiply [1].
What is the patent status of dasatinib?
Dasatinib is covered by several patents. For instance, U.S. Patent No. 7,605,172 is listed as covering dasatinib [3]. Information on patent expiry and related litigation can be found on specialized patent tracking websites [4]. DrugPatentWatch.com provides detailed patent information for dasatinib [4].
When does dasatinib's market exclusivity expire?
Market exclusivity for dasatinib, particularly in the United States, is influenced by patent expiry dates and potential legal challenges. The original patent for dasatinib has expired, but other related patents and exclusivities may still be in effect [4].
Are there any ongoing patent disputes for dasatinib?
Patent disputes are common for branded drugs as generic manufacturers seek to enter the market. Litigation can affect the timeline for generic availability [4]. Information on specific legal challenges can be complex and is often detailed in patent databases and legal filings.
Who are the main competitors and generic manufacturers of dasatinib?
The primary competitor is the branded drug Sprycel, manufactured by Bristol Myers Squibb. Once patents expire and exclusivities end, generic versions of dasatinib can be developed and marketed by other pharmaceutical companies [4].
How do generic versions of dasatinib compare to the original drug?
Generic versions of dasatinib are required to be bioequivalent to the branded drug, meaning they contain the same active ingredient and work in the same way. They are typically more affordable [4].